Similar articles

• Microbiological evaluation of cefpodoxime proxetil.

  Wiedemann B, Luhmer E, Zühlsdorf MT. Wiedemann B, et al. Drugs. 1991;42 Suppl 3:6-12. doi: 10.2165/00003495-199100423-00004. Drugs. 1991. PMID: 1726210
• Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

  Frampton JE, Brogden RN, Langtry HD, Buckley MM. Frampton JE, et al. Drugs. 1992 Nov;44(5):889-917. doi: 10.2165/00003495-199244050-00011. Drugs. 1992. PMID: 1280571 Review.
• Cefpodoxime proxetil in upper respiratory tract infections.

  Bergogne-Berezin E. Bergogne-Berezin E. Drugs. 1991;42 Suppl 3:25-33. doi: 10.2165/00003495-199100423-00007. Drugs. 1991. PMID: 1726205 Review.
• AS-924, a novel bifunctional prodrug of ceftizoxime.

  Kasai M, Hatano S, Kitagawa M, Yoshimi A, Shirahase H, Nishimura K, Kakeya N. Kasai M, et al. J Antibiot (Tokyo). 1999 May;52(5):491-500. doi: 10.7164/antibiotics.52.491. J Antibiot (Tokyo). 1999. PMID: 10480574
• Activity of cefpodoxime, an oral 3rd generation cephalosporin.

  Raymond N, Lang S. Raymond N, et al. N Z Med J. 1993 Feb 10;106(949):44. N Z Med J. 1993. PMID: 8464593 No abstract available.